Vertex Pharmaceuticals
VRTX
Market cap $120B

468.85 USD

-10.68

2.23%

At close Jul 11, 4:00 PM EDT

After hours

468.85

+0.00

0.00%

1 day

-2.23%

5 days

1.92%

1 month

3.63%

3 months

-3.17%

6 months

13.42%

Year to date

15.55%

1 year

-4.73%

5 years

64.61%

10 years

277.37%

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 206 | Existing positions closed: 126

63% more funds holding in top 10

Funds holding in top 10: 16 [Q4 2024] → 26 (+10) [Q1 2025]

29% more call options, than puts

Call options by funds: $771M | Put options by funds: $596M

20% more capital invested

Capital invested by funds: $95.5B [Q4 2024] → $114B (+$18.9B) [Q1 2025]

10% more repeat investments, than reductions

Existing positions increased: 626 | Existing positions reduced: 567

3% more funds holding

Funds holding: 1,534 [Q4 2024] → 1,583 (+49) [Q1 2025]

0.34% more ownership

Funds ownership: 91.6% [Q4 2024] → 91.94% (+0.34%) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$420

10%

downside

Avg. target

$489

4%

upside

High target

$550

17%

upside

7 analyst ratings

3 positive

43%

4 neutral

57%

0 negative

0%

HC Wainwright & Co. Andrew Fein	17%upside $550	Buy Reiterated	23 Jun 2025
Morgan Stanley Matthew Harrison	2%downside $460	Equal-Weight Maintained	20 Jun 2025
RBC Capital Brian Abrahams	10%downside $420	Sector Perform Maintained	17 Jun 2025
Scotiabank Greg Harrison	6%downside $442	Sector Perform Maintained	6 May 2025
JP Morgan Jessica Fye	10%upside $515	Overweight Maintained	6 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 19 articles about VRTX published over the past 30 days

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch

Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term data shows durable, life-changing benefits for SCD and TDT patients, but adoption is limited by a complex, intensive treatment process. Current Casgevy revenues are modest, but improvements to preconditioning and in-vivo approaches could unlock blockbuster potential by 2030.

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2025 Earnings Call.” The conference call will be webcast live and a link to the webcast can.

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

The Motley Fool

3 No-Brainer Stocks to Buy in July

Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.

3 No-Brainer Stocks to Buy in July

The Motley Fool

The Best Stocks to Invest $1,000 In Right Now

Forget the market sell-off experienced earlier this year. Stocks are hot again.

The Best Stocks to Invest $1,000 In Right Now

Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts

Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further.

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

See News Rankings

Charts implemented using Lightweight Charts™